[{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Won & Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Series A Financing","leadProduct":"Supernova 1","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ Won & Partners","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Biotherapeutics \/ Won & Partners"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"CAL1 vaccinia virus","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Calidi Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Cerecor","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"CERC-006","moa":"mTOR 1\/2 complex","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calidi Biotherapeutics \/ Calidi Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Calidi Biotherapeutics \/ Calidi Biotherapeutics"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Calidi Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"NNV1","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Calidi Biotherapeutics \/ Calidi Biotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Calidi Biotherapeutics \/ Calidi Biotherapeutics"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"City of Hope","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Allogeneic Neural Stem Cell","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ Calidi Biotherapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Calidi Biotherapeutics \/ Calidi Biotherapeutics"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AD-MSC Based Oncolytic Virus","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Calidi Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AD-MSC Based Oncolytic Virus","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Calidi Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"CIRM","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Funding","leadProduct":"AD-MSC-based Oncolytic Virus","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ CIRM","highestDevelopmentStatusID":"4","companyTruncated":"Calidi Biotherapeutics \/ CIRM"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Jackson Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Series B Financing","leadProduct":"NSC-CRAd-S-pk7","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Calidi Biotherapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Calidi Biotherapeutics \/ Jackson Investment Group","highestDevelopmentStatusID":"6","companyTruncated":"Calidi Biotherapeutics \/ Jackson Investment Group"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"NSC.CRAd-S-pk7","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Calidi Biotherapeutics \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"Calidi Biotherapeutics \/ City of Hope"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Ladenburg Thalmann","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"CLD-101","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calidi Biotherapeutics","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ Ladenburg Thalmann","highestDevelopmentStatusID":"5","companyTruncated":"Calidi Biotherapeutics \/ Ladenburg Thalmann"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Ladenburg Thalmann","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"CLD-101","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ Ladenburg Thalmann","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Biotherapeutics \/ Ladenburg Thalmann"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"SIGA Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"CLD-400","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ SIGA Technologies","highestDevelopmentStatusID":"2","companyTruncated":"Calidi Biotherapeutics \/ SIGA Technologies"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"CLD-101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Calidi Biotherapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Calidi Biotherapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : CLD-101 is a novel stem-cell based platform designed to deliver oncolytic viruses to tumors. It is beinf evaluated for the treatment of newly diagnosed high grade glioma.

                          Brand Name : CLD-101

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          September 30, 2024

                          Lead Product(s) : CLD-101

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : The collaboration aims to support the development of Calidi’s systemic and targeted RTNova (CLD-400) virotherapy platform, which has the potential to provide a universal treatment for all tumor types.

                          Brand Name : CLD-400

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          June 10, 2024

                          Lead Product(s) : CLD-400

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : SIGA Technologies

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : The company intends to use the net proceeds from this offering to advance the clinical development of NeuroNova (CLD-101) for treating high-grade glioma.

                          Brand Name : CLD-101

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          May 31, 2024

                          Lead Product(s) : CLD-101

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Ladenburg Thalmann

                          Deal Size : $2.1 million

                          Deal Type : Public Offering

                          blank

                          04

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : The net proceeds will be used for the advancement of company's CLD-101 designed to protect and better distribute the anti-cancer virus to sites of tumors distant from the main tumor mass.

                          Brand Name : CLD-101

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          April 19, 2024

                          Lead Product(s) : CLD-101

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Ladenburg Thalmann

                          Deal Size : $6.1 million

                          Deal Type : Public Offering

                          blank

                          05

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : CLD-101 platform, which includes NSC.CRAd-S-pk7, is an allogeneic, “off-the-shelf” therapy comprised of an immortalized NSC line loaded with an engineered oncolytic adenovirus.

                          Brand Name : CLD-101

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          July 18, 2023

                          Lead Product(s) : NSC.CRAd-S-pk7

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : City of Hope

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : The financing will enable Calidi to continue the advancement of its pipeline including CLD-101, CLD-201, and CLD-202, which utilize a potent allogeneic stem cell and oncolytic virus combination for use in multiple oncology indications.

                          Brand Name : CLD-101

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          June 23, 2023

                          Lead Product(s) : NSC-CRAd-S-pk7

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Jackson Investment Group

                          Deal Size : $25.0 million

                          Deal Type : Series B Financing

                          blank

                          07

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : SNV1 is composed of allogeneic, adipose-derived mesenchymal stem cells (AD-MSC Based Oncolytic Virus) loaded with the oncolytic vaccinia virus Cal1, targeting a variety of solid tumors including metastatic melanoma, triple negative breast cancer, and adv...

                          Brand Name : SNV1

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          December 14, 2022

                          Lead Product(s) : AD-MSC-based Oncolytic Virus

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : CIRM

                          Deal Size : $3.1 million

                          Deal Type : Funding

                          blank

                          08

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : SNV1 (AD-MSC based oncolytic virus) is an AD-MSC-delivering CAL1 oncolytic virus used for the treatment of solid tumors (metastatic breast, melanoma, head and neck).

                          Brand Name : SNV1

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          October 12, 2022

                          Lead Product(s) : AD-MSC Based Oncolytic Virus

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : The SNV platform is composed of allogeneic, adipose-derived mesenchymal stem cells (AD-MSC) loaded with an oncolytic agent, such as the vaccinia virus SNV1, and is anticipated to be used in combination with various immunotherapy agents, including blockin...

                          Brand Name : SNV1

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          May 24, 2022

                          Lead Product(s) : AD-MSC Based Oncolytic Virus

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : The agreement grants to Calidi commercial exclusivity in using neural stem cells with the adenovirus known as CRAd-pk-S-7 for oncolytic virotherapy.

                          Brand Name : CRAd-pk-S-7

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          August 16, 2021

                          Lead Product(s) : CRAd-pk-S-7,Allogeneic Neural Stem Cell

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Recipient : City of Hope

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank